Quantcast

Latest Clostridium difficile Stories

2014-10-20 08:26:49

New ACG Blog Offers Author Insights, Abstract Access, Breaking News BETHESDA, Md., Oct. 20, 2014 /PRNewswire-USNewswire/ -- Promising new research in the area of hepatitis C (HCV) therapy that suggests more patients, including those with cirrhosis, will be cured from this common cause of potentially fatal viral liver disease; as well as a number of abstracts that advance understanding of the safety and effectiveness of fecal microbiota transplantation for Clostridium difficile, are...

fecal pills
2014-10-14 03:00:49

Provided by Noah Brown, The JAMA Network Journals A preliminary study has shown the potential of treating recurrent Clostridium difficile infection (a bacterium that is one of the most common causes of infection of the colon) with oral administration of frozen encapsulated fecal material from unrelated donors, which resulted in an overall rate of resolution of diarrhea of 90 percent, according to a study published in JAMA. The study is being released early online to coincide with its...

2014-10-09 12:28:58

Results for groundbreaking multi-center study of lead drug candidate RBX2660 (microbiota suspension) presented at IDWeek 2014 PHILADELPHIA, Oct. 9, 2014 /PRNewswire/ -- Rebiotix Inc. announced today that results of the Phase 2 PUNCH(TM) CD Study found that the overall efficacy of RBX2660 in the treatment of recurrent Clostridium difficile infection was 87.1%. The study also found that administration of RBX2660 was well-tolerated and demonstrated satisfactory safety in the 60-day...

2014-10-01 12:31:15

Rebiotix lead drug candidate RBX2660 (microbiota suspension) assessed in PUNCH CD study ROSEVILLE, Minn., Oct. 1, 2014 /PRNewswire/ -- Rebiotix Inc. announced this morning that results of PUNCH CD, a Phase 2 study of the company's lead product candidate, RBX2660 (microbiota suspension), will be presented in three posters at the American College of Gastroenterology (ACG) Annual Scientific Meeting in Philadelphia from October 17-22. The following poster will be presented on Monday, October 20,...

2014-09-23 12:29:47

CHICAGO, Sept. 23, 2014 /PRNewswire-USNewswire/ -- C Diff Foundation is proud to present the 2014 "Raising C.difficile Awareness" conference. Join us November 4(th) at 8 a.m. - 5 p.m. at the University of Illinois at Chicago, Student Center, West 828 S. Wolcott Avenue, Thompson Room, Chicago, IL. World renowned topic experts will be presenting data for C. difficile and Hospital-Acquired Infection (HAI) prevention, treatments, and environmental safety. To view the conference details,...

2014-09-17 12:27:55

Rebiotix microbiota-based drug candidate used to assess a non-antibiotic approach to an urgent public health threat ROSEVILLE, Minn., Sept. 17, 2014 /PRNewswire/ -- Rebiotix Inc. announced this morning that results of the Phase 2 study of the company's lead product candidate, RBX2660 (microbiota suspension) will be presented in two posters and a podium presentation during the IDWeek 2014 conference in Philadelphia from October 8-12. PUNCH CD study results will be presented during the poster...

2014-09-17 04:21:26

GLASGOW, Scotland, September 17, 2014 /PRNewswire/ -- First antibacterial with a new mode of action from a truly novel class of anti-infective in over a decade MGB Biopharma, a biopharmaceutical company developing a truly novel class of anti-infectives, announces today that it has secured GBP4.0m ($6.4m) to advance the development of its lead antibacterial, MGB-BP-3, against a range of Gram-positive infections including Clostridium...

2014-09-16 12:30:33

-- Mark Pimentel, M.D., of Cedars-Sinai Delivered Keynote Presentation on Mechanism of Action -- ROCKVILLE, Md., Sept. 16, 2014 /PRNewswire/ -- Synthetic Biologics, Inc. (NYSE MKT: SYN), a biotechnology company developing novel anti-infective biologic and drug programs targeting specific pathogens that cause serious infections and diseases, announced today the completion of the Company's Investor Day in New York which highlighted its irritable bowel syndrome (IBS) program, including...

2014-09-11 08:27:38

-- Conference Call Scheduled for Friday, September 12, 2014, at 9:15 a.m. EDT -- ROCKVILLE, Md., Sept. 11, 2014 /PRNewswire/ -- Synthetic Biologics, Inc. (NYSE MKT: SYN), a biotechnology company developing novel anti-infective biologic and drug candidates targeting specific pathogens that cause serious infections and diseases, announced today that it will host a an investor conference call on Friday, September 12, 2014, at 9:15 a.m. EDT. The conference call will highlight...

2014-09-10 12:29:04

-- Keynote Speaker: Mark Pimentel, M.D., FRCP(C), Director, GI Motility Program and Laboratory, Cedars-Sinai Medical Center; Chairman, Synthetic Biologics' C-IBS Clinical Advisory Board -- ROCKVILLE, Md., Sept. 10, 2014 /PRNewswire/ -- Synthetic Biologics, Inc. (NYSE MKT: SYN), a biotechnology company developing novel anti-infective biologic and drug candidates targeting specific pathogens that cause serious infections and diseases, announced today that its Investor Day to highlight...


Latest Clostridium difficile Reference Libraries

0_9f897835bb09adc2a84fda23893d87f8
2011-04-15 13:50:01

Clostridium difficile, also known as "CDF/cdf", or "C. diff", is a Gram-positive bacteria of the genus Clostridium that causes severe diarrhea and other intestinal disease when competing bacteria in the gut flora are wiped out by antibiotics. They are anaerobic, spore-forming rods and is the most serious cause of antibiotic-associated diarrhea and potentially to pseudomembranous colitis. C. difficile bacteria naturally resides in the gut of a small percentage of the adult population. Others...

More Articles (1 articles) »
Word of the Day
conjunto
  • A style of popular dance music originating along the border between Texas and Mexico, characterized by the use of accordion, drums, and 12-string bass guitar and traditionally based on polka, waltz, and bolero rhythms.
The word 'conjunto' comes through Spanish, from Latin coniūnctus, past participle of coniungere, to join together; see conjoin